Navigation Links
Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere's Disease
Date:12/11/2013

SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease. The company also announced that the U.S. Food and Drug Administration (FDA) has granted OTO-104 Fast Track designation, a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

This prospective, randomized, double-blind, placebo-controlled Phase 2b study is designed to assess the efficacy and safety of OTO-104 for the treatment of Meniere's disease in a total of 140 patients at approximately 50 centers in the United States and Canada. The primary endpoint is the reduction in vertigo frequency at week 12, measured during the 4-week interval from week 9 through week 12, compared to baseline. Otonomy expects to complete patient enrollment of the trial by mid-2014 and announce top line results during the fourth quarter of 2014.

"The commencement of enrollment marks an important clinical milestone for the advancement of OTO-104 as we expect this trial will serve as one of the two studies required to demonstrate efficacy for approval in the United States," said David A. Weber, Ph.D., president and CEO of Otonomy. "The FDA's Fast Track designation shows that the agency recognizes the potential for this product to address the important unmet medical need in Meniere's disease."

Added Paul R. Lambert, M.D., professor and c
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Otonomy Completes $45.9 Million Series C Equity Financing
2. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
3. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
4. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
5. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
6. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
7. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
8. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
9. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
10. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... England , July 22, 2014 ... development and device company focused on solid dose ... its novel solid formulation of octreotide acetate achieved ... it with the currently marketed liquid product (Sandostatin®). ... transfer the formulation production process to a contract ...
(Date:7/21/2014)... /PRNewswire-iReach/ -- Nitrosolution.com, a website that features safe and ... first anniversary in August. The online retailer specializes in ... body,s ability to produce nitric oxide. Called Nitroxyl, it ... a variety of phytonutrients and other natural ingredients that ... nitric oxide production in the arteries and ...
(Date:7/21/2014)... , July 21, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... operating results for the second quarter of fiscal year ... will hold a conference call to discuss its financial ... at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern ...
Breaking Medicine Technology:Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2Thoratec Schedules Second Quarter Conference Call, Webcast 2
... 12 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... drug (IND) application to the U.S. Food and ... for rheumatoid,arthritis and other autoimmune conditions. The initial ... a double-blind, randomized,placebo-controlled, ascending single-dose study in healthy ...
... Medical Lasers Limited,(ASX: ELX), a global leader in ... systems, announced today initial clinical results of,an ongoing ... demonstrate the therapy,s potential to improve and,stabilize visual ... with,diabetic maculopathy and macular edema without causing any ...
Cached Medicine Technology:Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 4
(Date:7/22/2014)... One of the largest studies ever conducted into the ... new sites on chromosomes that harbor inherited genes tied ... team of researchers, now bring the total number of ... Although these schizophrenia-associated genes aren,t specific enough ... will or will not develop the illness, researchers say ...
(Date:7/22/2014)... July 22, 2014 CarePoint Health is pleased ... as the President of the medical staff at Bayonne Medical ... serve as President, as voted on by the physicians on ... medical staff in relation to the administration at Bayonne Medical ... physicians and to work to make the Medical Center the ...
(Date:7/22/2014)... The donation from the Edusei Foundation was greatly ... a feat of strategic engineering, such assistance tends to etch ... the beneficiaries. It provided a sense of family to them, ... Edusei Foundation donated various amounts of; milk, soap, ... , The Government of Ghana established the Kumasi Children’s Home ...
(Date:7/22/2014)... 2014 Hospitals & Health ... conducted by Hospitals & Health Networks in ... CareTech Solutions, The College of Healthcare Information ... list recognizes hospitals for successful health information ... in four focus areas: business and administrative ...
(Date:7/22/2014)... TUESDAY, July 22, 2014 (HealthDay News) -- People who ... risk for a rise in blood pressure, a new ... major health problems and even early death, but few ... trouble may be one of the causes, according to ... 138 people who had been separated or divorced for ...
Breaking Medicine News(10 mins):Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2Health News:Edusei Foundation Donates Food and Needed Items to Kumasi Children’s Home in Ashanti Region of Ghana 2Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 2Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 3Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2
... The Association for Research in Vision and Ophthalmology ... distinguished fellows. The title of Fellow of ARVO (FARVO) ... the Association. By accepting this honor, ARVO anticipates ... and mentors for individuals pursuing careers in vision and ...
... be important in cardiac development has been newly associated ... the left ventricular outflow tract. These are the findings ... appearing in the journal Birth Defects Research Part ... including aortic valve stenosis, coarctation of the aorta, hypoplastic ...
... tomography (PET) in patients with head and neck tumours, ... cannot currently be reliably assessed. This is the result ... for Quality and Efficiency in Health Care (IQWiG). The ... to assess the advantages and disadvantages of this diagnostic ...
... prostate-rectal inter-space is an effective way to reduce the ... according to research presented April 30, 2011, at the ... symposium is sponsored by the American Society for Radiation ... Even though prostate cancer is cured in over 90 ...
... Combining computerized tomography (CT) with fluorodeoxyglucose positron emission ... tumor outlines and potentially different treatment options in ... CT alone, according to research presented today, at ... Atlanta. This symposium is co-sponsored by the American ...
... of hospitalization have discouraged primary care doctors from seeing ... use of "hospitalists," a new physician specialty focused on ... field mean that frequently hospitalized patients also may need ... expert on hospital care at the University of Chicago. ...
Cached Medicine News:Health News:2011 ARVO Fellows announced 2Health News:Study identifies second gene associated with specific congenital heart defects 2Health News:Benefit of PET in patients with head and neck tumors cannot be assessed 2Health News:Benefit of PET in patients with head and neck tumors cannot be assessed 3Health News:Benefit of PET in patients with head and neck tumors cannot be assessed 4Health News:Tissue spacers reduce risk of rectal injury for prostate cancer patients 2Health News:Frequently hospitalized patients may benefit from new medical specialty focused on their needs 2
... To aid clinicians in performing Ankle/Brachial ... a new, complete packet of information. It ... presentation that can be viewed on any ... the step-by-step procedure of performing an ABI ...
... Auto Refractor/Keratometer. Advanced engineering, ... retro illumination mode make it the ... use. 5.5 inch High Quality ... focusing. Rapid, instantaneous readings are taken ...
... for Urinary Tract Infection (UTI) ... A multi-center study was conducted ... UTIs. There were 1,887 urine ... and nitrite results of Multistix ...
... PocketChem UA is the first ... take up valuable lab bench space. ... the variability in results between operators ... on every run, corrects for ambient ...
Medicine Products: